Biogen's Q2 2026: A Growth Portfolio Keeps the Engine Warm, If Not Boiling Over

Headline numbers

Biogen reported total revenue of $2.7 billion for Q2 2026, up 3% year over year. The Growth Portfolio, which Biogen defines as a collection including SPINRAZA, SKYCLARYS, SYFOVRE, VUMERITY, LEQEMBI, ZURZUVAE, EMPAVELI, and QALSODY, generated $1.06 billion in revenue, representing a 24% YoY increase. The press release underscores that the Growth Portfolio now carries Biogen’s 50% share of net revenue and cost of sales, including royalties, from the LEQEMBI Collaboration.

Product-by-product highlights in the Growth Portfolio

• SPINRAZA revenue: $402 million, up 2% YoY.
• VUMERITY revenue: $197 million, down 7% YoY, with dynamics rooted in inventory and base effects.
• LEQEMBI global in-market sales: $184 million, up 15%; U.S. in-market sales: $97 million, signaling continued domestic strength and international expansion in parallel.
• LEQEMBI IQLIK: FDA-approved, enabling at-home initiation—a notable logistical shift in administration.
• SKYCLARYS revenue: $168 million, up 29% YoY as the portfolio leverages the Europe and select international markets.
• ZURZUVAE revenue: $71 million, up 53% YoY, driven by renewed demand and increased access outside the U.S.
• SYFOVRE revenue: $162 million for the full quarter, up 8% YoY; $97 million of revenue recognized by Biogen after the Apellis acquisition closed on May 14, 2026.
• EMPAVELI revenue: $46 million for the full quarter, up 123% YoY, supported by demand growth and late-stage expansion; Biogen recognized $30 million of revenue post-close of the Apellis acquisition.

In short, the Growth Portfolio is the star performer and the heavy lifting comes from the portfolio’s mix of established products plus newly integrated lines from Apellis. The company also provides a helpful footnote: the Growth Portfolio includes EMPAVELI, QALSODY, SKYCLARYS, SPINRAZA, SYFOVRE, VUMERITY, ZURZUVAE, plus Biogen’s 50% share of LEQEMBI-related revenue and costs of sales, including royalties.

Earnings details and guidance context

Biogen shows GAAP diluted EPS of $0.66 and Non-GAAP diluted EPS of $3.60 for the quarter. The release flags deal-related charges tied to historical transactions related to IPR&D and the Apellis acquisition, and notes ongoing investment in Phase 3 development programs. The document does not present a formal EPS consensus or revenue forecast from external analysts, which means readers are left to interpret whether Biogen’s internal pacing aligns with broader expectations.

In the broader context, the company frames the quarter as a marker of progress toward its goal of sustainable revenue growth, especially as the Growth Portfolio dilutes risk across multiple therapies and geographies. It’s not a single blockbuster—but it’s several mid-to-large revenue streams working in concert, with a notable acceleration in 123% YoY growth for EMPAVELI and meaningful contributions from the LEQEMBI and SYFOVRE franchises after M&A activity.

Acquisitions and strategic positioning

The Apellis acquisition closed on May 14, 2026, and Biogen is now reflecting post-close revenue recognition in the Growth Portfolio figures. The commentary emphasizes the company’s repositioning toward sustainable growth with a growing commercial base, a multi-year late-stage data pipeline, and an expanding early-stage program. The combination of in-market products and new initiation mechanisms (like LEQEMBI IQLIK) suggests Biogen is leaning into convenience and patient access as a lever for growth, rather than relying solely on headline drug launches.

CEO commentary and forward look

CEO Christopher Viehbacher frames the quarter as evidence of “significant progress Biogen has made repositioning the company for long-term growth.” The statement signals an ongoing focus on execution across a diversified portfolio, the integration of recent acquisitions, and a pipeline that could deliver data readouts in the years ahead. The tone is pragmatic rather than celebratory, with an emphasis on building a platform that can weather regulatory, pricing, and competitive headwinds in CNS therapies.

Industry implications for Biogen and peers

Biogen’s mixed-growth narrative—steady SPINRAZA and SYFOVRE demand, a reaccelerating LEQEMBI, and a high-growth EMPAVELI—highlights a path other neurodegenerative players might emulate: diversify revenue sources, pursue selective acquisitions to fill therapy gaps, and push for improved administration models (at-home initiation, streamlined dosing). The regulatory backdrop around anti-amyloid therapies and the evolving competitive landscape mean peers will be watching Biogen's integration and go-to-market execution as a case study in leveraging a portfolio approach rather than a single-therapeutic bet.